Medical Management of Women with Breast Cancer | ||||
| Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology | ||||
| Article 16, Volume 13, Issue 2, December 2021, Page 211-213 PDF (515.64 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/eajbsc.2021.207512 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| K. Hammara1; S. Moulessehoula1; A. Tou2 | ||||
| 1Biotoxicology Laboratory, Department of Biology, Faculty of Nature and Life Sciences, Djillali Liabés University, BP 89, Sidi Bel Abbes, Algeria. | ||||
| 2Department of Pathological Anatomy, Faculty of Medicine, Sidi Bel Abbes University Hospital, Sidi Bel Abbes, Algeria | ||||
| Abstract | ||||
| Breast cancer in Algeria, like everywhere else in the world, is a major public health problem. For several years, women with breast cancer have benefited from increasingly effective and more and more personalized treatments, the management of which depends on the stage of development of the tumor, its characteristics, age and condition. patient's state of health. Since the 2000s, patients admitted to the pathological anatomy service of the CHU of Sidi bel abbés have been systematically evaluated HER2, in order to recruit those who could benefit from targeted therapy (HerceptinÒ). Comes after the evaluation of the amplification status of this gene by fluorescence in situ hybridization (FISH) of intermediate scores (HER2 score 2). Other markers are evaluated for women with this cancer, for better therapeutic management (hormone receptors, Ki67, etc.), see monitoring in the event of a possible relapse. | ||||
| Keywords | ||||
| Breast cancer; Biological parameters; Immunohistochemistry | ||||
|
Statistics Article View: 185 PDF Download: 218 |
||||
